Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer

NCT01031875 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT01031875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01031875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
August 31, 2012
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer